reports
Editas Medicine Announces Second Quarter 2025 Results and Business Upd...
Editas Medicine Announces Second Quarter 2025 Results and Business Updates Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Presented data at ASGCT, TIDES, and EHA that validate differentiated potential of Editas’ gene upregulation strategy and in vivo delivery platform technology Strong cash position with operational runway into the se...
- Jonathan Moreland
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TFX TELEFLEX INCORPORATED
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SHBI SHORE BANCSHARES INC.
PNFP PINNACLE FINANCIAL PARTNERS INC.
OPK OPKO HEALTH INC.
NSP INSPERITY INC.
NPO ENPRO INDUSTRIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
LLY ELI LILLY AND COMPANY
KMPR KEMPER CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
EIG EMPLOYERS HOLDINGS INC.
CNOB CONNECTONE BANCORP INC.
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CHD CHURCH & DWIGHT CO. INC.
CDXS CODEXIS
ARW ARROW ELECTRONICS INC.
AMH AMERICAN HOMES 4 RENT CLASS A
CIVB CIVISTA BANCSHARES
OLN OLIN CORPORATION
ASUR ASURE SOFTWARE INC
BRO BROWN & BROWN INC.
CYRX CRYOPORT INC.
FTV FORTIVE CORP.
CLAR CLARUS CORPORATION
A2H9KJ NEO PERFORMANCE MATERIAL
OSPN ONESPAN
FXNC FIRST NATIONAL CORP. OF VIRGINIA
TROX TRONOX HOLDINGS PLC
MEC MAYVILLE ENGINEERING
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
XRX XEROX HOLDINGS CORPORATION
PINE ALPINE INCOME PROPERTY TRUST
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
LRMR LARIMAR THERAPEUTICS INC
THRY THRYV HOLDINGS
DLHC DALEIGH HOLDINGS CORP
INTA INTAPP INC
PTLO PORTILLOS INC
BRBR BELLRING BRANDS INC
AUB ATLANTIC UNION BANKSHARES CORP
AURX NUO THERAPEUTICS
OI INC.
SIRI OWENS ILLINOIS INC.
XELB SIRIUS XM HLDGS INC NEW
MUSA XCEL BRANDS INC.
LNW METALS USA HOLDINGS CORP.
LIGHT & WONDER INC.
International Flavors & Fragrances Inc: 2 directors
A director at International Flavors & Fragrances Inc bought 15,450 shares at 64.802USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
- Jonathan Moreland
PNFP PINNACLE FINANCIAL PARTNERS INC.
OPK OPKO HEALTH INC.
NPO ENPRO INDUSTRIES INC.
LLY ELI LILLY AND COMPANY
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
BRO BROWN & BROWN INC.
CRSP CRISPR THERAPEUTICS AG
OSPN ONESPAN
TROX TRONOX HOLDINGS PLC
MEC MAYVILLE ENGINEERING
PINE ALPINE INCOME PROPERTY TRUST
PTLO PORTILLOS INC
AUB ATLANTIC UNION BANKSHARES CORP
LNW LIGHT & WONDER INC.
- Jonathan Moreland
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TFX TELEFLEX INCORPORATED
KMPR KEMPER CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
AMH AMERICAN HOMES 4 RENT CLASS A
OLN OLIN CORPORATION
CZWI CITIZENS COMMUNITY BANCORP
CLAR CLARUS CORPORATION
LOOP LOOP INDUSTRIES
FXNC FIRST NATIONAL CORP. OF VIRGINIA
TROX TRONOX HOLDINGS PLC
AUB ATLANTIC UNION BANKSHARES CORP
OI OWENS ILLINOIS INC.
Kinder Morgan Inc: 2 directors
Two Directors at Kinder Morgan Inc sold after exercising options/sold 85,549 shares at between 27.961USD and 28.193USD. The significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all t...
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delive...
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIR...
Post Holdings Inc: 2 directors
Two Directors at Post Holdings Inc sold/bought 188,490 shares at between 108.973USD and 109.115USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
- Jonathan Moreland
CMI CUMMINS INC.
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
OEC ORION ENGINEERED CARBONS SA
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUM HUMANA INC.
GLP GLOBAL PARTNERS LP
BRKR BRUKER CORPORATION
ASYS AMTECH SYSTEMS INC.
ERII ENERGY RECOVERY INC.
ELY CALLAWAY GOLF COMPANY
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
GCBC GREENE COUNTY BANCORP INC.
WINA WINMARK CORP.
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
NNBR NN
LILA INC.
COLD LIBERTY LATIN AMERICA A
EAF AMERICOLD REALTY TRUST
ULBI GRAFTECH INTERNATIONAL
MIDD ULTRALIFE
ENR THE MIDDLEBY CORPORATION
RPAY EDGEWELL PERSONAL CARE COMPANY
PRG REPAY HOLDINGS (A)
LESL PROG HOLDINGS
GRNT INC.
ALKT LESLIES
CVRX GRANIT SKOPKE
MINM ALKAMI TECHNOLOGY
MYO INC.
FLNC CVRX
DCGO INC.
STGW MINIM
OGN INC.
PFHC MYOMO
RXO_w FLUENCE ENERGY INC
OABI DOCGO INC
WEST STAGWELL INC
SRPT ORGANON & CO
FTK PROFRAC HLDG CORP
TXO RXO INC
AESI OMNIAB INC
FINS WESTROCK COFFEE COMPANY LLC
SAREPTA THERAPEUTICS
INC.
FLOTEK INDUSTRIES INC.
MORNINGSTAR PARTNERS
L.P.
ATLAS ENERGY SOLUTIONS INC.
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
GOGO GOGO INC.
ERII ENERGY RECOVERY INC.
ELY CALLAWAY GOLF COMPANY
GCBC GREENE COUNTY BANCORP INC.
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
PMTS INC.
PNBK CPI CARD GROUP
EAF PATRIOT NATIONAL BANCORP
ULBI GRAFTECH INTERNATIONAL
ENR ULTRALIFE
PHAT EDGEWELL PERSONAL CARE COMPANY
LPI PHATHOM PHARMACEUTICALS
LESL LAREDO PETROLEUM INC.
MYO LESLIES
FLNC MYOMO
DCGO FLUENCE ENERGY INC
OGN DOCGO INC
TCBX ORGANON & CO
OABI THIRD COAST BANCSHARES INC
WEST OMNIAB INC
SRPT WESTROCK COFFEE COMPANY LLC
FTK SAREPTA THERAPEUTICS
BNL INC.
DMA FLOTEK INDUSTRIES INC.
SUNS BROADSTONE NET LEASE INC
EVM DESTRA MULTI ALTERNATIVE FUND
TXO SUNRISE REALTY TRUST
FG EATON VANCE INSD CALIF MUN BD FD
EU MORNINGSTAR PARTNERS
IAE L.P.
AESI F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
ATLAS ENERGY SOLUTIONS INC.
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistr...
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene ...
Editas Medicine Reports New In Vivo Data Highlighting the Potential of...
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 p...
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisc...
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared in vivo proof of concept data supporting the development of a potentially first-in-class treatment for an undisclosed liver target in a poster presentation...
Editas Medicine Announces First Quarter 2025 Results and Business Upda...
Editas Medicine Announces First Quarter 2025 Results and Business Updates Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to upregulate expression of a target liver protein to meaningfully reduce a common disease-associated biomarker at ASGCT this week and TIDES next week Remains on track to declare two in vivo gene editing development candidates via gene upregu...
Editas Medicine Announces U.S. Court of Appeals for the Federal Circui...
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and Appeal Board’s (PTABs) previous decision and remanded it back to the PTAB for further review in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the...
- Jonathan Moreland
RGR STURM RUGER & COMPANY INC.
PEB PEBBLEBROOK HOTEL TRUST
PCAR PACCAR INC
NG. NOVAGOLD RESOURCES INC.
NBTB NBT BANCORP INC.
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUN HUNTSMAN CORPORATION
HL HECLA MINING COMPANY
CHDN CHURCHILL DOWNS INCORPORATED
CFFN CAPITOL FEDERAL FINANCIAL INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BIIB BIOGEN INC.
APLE APPLE HOSPITALITY REIT INC
OFIX ORTHOFIX INTERNATIONAL N.V.
CAT CATERPILLAR INC.
ARCB ARCBEST CORPORATION
HTLD HEARTLAND EXPRESS INC.
USAC USA COMPRESSION PARTNERS LP
NHC NATIONAL HEALTHCARE CORP.
JELD JELD-WEN HOLDING INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
OCSL OAKTREE SPECIALTY LENDING CORPORATION
SNBR SLEEP NUMBER CORPORATION
RCII RENT-A-CENTER INC
A2H9KJ NEO PERFORMANCE MATERIAL
KKR KKR & CO. INC.
REZI RESIDEO TECHNOLOGIES
TROX INC.
UTGN TRONOX HOLDINGS PLC
CCO UTG
AVTR CLEAR CHANNEL OUTDOOR HOLDINGS INC
GCI AVANTOR
DCTH INC.
ONEW GANNETT CO. INC.
DLHC DELCATH SYSTEMS
UTZ ONEWATER MARINE
OGN DALEIGH HOLDINGS CORP
NVCT UTZ BRANDS INC (A)
PRAA ORGANON & CO
VSTS_w NUVECTIS PHARMA INC
BNL PORTFOLIO RECOVERY ASSOCIATES
DMA INC.
SUNS VESTIS CORPORATION
GF BROADSTONE NET LEASE INC
FG DESTRA MULTI ALTERNATIVE FUND
EU SUNRISE REALTY TRUST
ECF THE NEW GERMANY FUND
HCWB INC.
F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
ELLSWORTH FUND LTD
HCW BIOLOGICS INC
- Jonathan Moreland
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
ARCB ARCBEST CORPORATION
SNBR SLEEP NUMBER CORPORATION
A2H9KJ NEO PERFORMANCE MATERIAL
REZI RESIDEO TECHNOLOGIES
TROX INC.
AVTR TRONOX HOLDINGS PLC
DCTH AVANTOR
ONEW INC.
NVCT DELCATH SYSTEMS
PRAA ONEWATER MARINE
VSTS_w NUVECTIS PHARMA INC
BNL PORTFOLIO RECOVERY ASSOCIATES
SUNS INC.
FG VESTIS CORPORATION
HCWB BROADSTONE NET LEASE INC
SUNRISE REALTY TRUST
F AND G ANNUITIES AND LIFE
INC.
HCW BIOLOGICS INC
Editas Medicine to Announce First Quarter 2025 Financial Results and t...
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine mana...
Editas Medicine to Present Preclinical Data Demonstrating Progress in ...
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting pr...
- Jonathan Moreland
ULTA ULTA BEAUTY INC
STAA STAAR SURGICAL CO.
SIGI SELECTIVE INSURANCE GROUP INC.
SIG SIGNET JEWELERS LIMITED
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PSEC PROSPECT CAPITAL CORPORATION
PEB PEBBLEBROOK HOTEL TRUST
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
OMCL OMNICELL INC.
MTDR MATADOR RESOURCES COMPANY
MEI METHODE ELECTRONICS INC.
JCOM J2 GLOBAL INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUN HUNTSMAN CORPORATION
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HSC
I3N HARSCO CORPORATION
FSS CHART INDUSTRIES INC.
EVH FEDERAL SIGNAL CORPORATION
ECPG EVOLENT HEALTH INC CLASS A
CMC ENCORE CAPITAL GROUP INC.
APPS COMMERCIAL METALS COMPANY
AMRC DIGITAL TURBINE
ADBE AMERESCO
HRTG ADOBE INC.
FMC HERITAGE INSURANCE HOLDINGS INC.
MAC FMC CORPORATION
LIVE MACERICH COMPANY
FLGT LIVE VENTURES
FCNCA FULGENT GENETICS
DMLP FIRST CITIZENS BANCSHARES INC. CLASS A
RCII DORCHESTER MINERALS L.P.
FTDR RENT-A-CENTER INC
NFE FRONTDOOR INC.
GRWG NEW FORTRESS ENERGY
PCB GROWGENERATION
CMPR PACIFIC CITY FINANCIAL CORP
RC CIMPRESS PLC
ACA GRUPO RADIO CENTRO S.A.B. DE C.V.
RZLT ARCOSA
ONEW REZOLUTE
PRLD INC.
FET ONEWATER MARINE
IMNM PRELUDE THERAPEUTICS
CMTG FORUM ENERGY TECHNOLOGIES
LYEL IMMUNOME
BTMD CLAROS MORTGAGE TRUST
IE INC.
EBC LYELL IMMUNOPHARMA INC
MODD HAYMAKER ACQUISITION CORP III
MRNA IVANHOE ELECTRIC INC
FG EASTERN BANKSHARES INC
MODULAR MEDICAL INC
MODERNA
INC.
F AND G ANNUITIES AND LIFE
INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.